LONDON, August 29 /PRNewswire/ -- Molecular diagnostics is one of the fastest growing areas in the European in vitro diagnostics (IVD) market. To maximise on the tremendous growth potential of molecular diagnostics, market participants will need to effectively communicate with healthcare providers, and keep them updated on technological advancements as well as the availability of new tests.
Frost & Sullivan (http://www.healthcare.frost.com) finds that the European Molecular Diagnostics Markets earned revenues of $517.5 million in 2005 and estimates this to reach $987.5 million in 2012.
“Early diagnosis and technological superiority over immunoassays are the key factors driving the wider adoption of molecular tests in Europe,” notes Frost & Sullivan Research Associate Arun AK. “An emphasis on enhanced patient care, better therapeutic options and population screening programmes are boosting the uptake of tests.”
Automated and integrated molecular diagnostic solutions have improved the assay performance by decreasing the complexity involved in a molecular test. Despite the relatively high price of these solutions, their inherent benefits, including reduced labour requirements and low cost per assay will support their adoption.
“However, market success will depend to a large extent on effective communication,” cautions Mr. Arun. “Manufacturers will need to communicate the value of their technologies to healthcare regulators, payers, providers and patients.”
Many molecular diagnostic assays are novel in the information they provide to the physician and the patient. Therefore, creating awareness and educating healthcare providers and patients alike will be necessary both for the success of the assay and also to qualify for reimbursement.
“Molecular diagnostics companies must conduct awareness programmes aimed at educating physicians on developments in pharmacogenomics and cancer diagnosis, in addition to infectious disease screening,” advises Mr. Arun. “As recommendations by physicians and cancer association groups strongly influence the adoption of molecular tests, such awareness programmes will be critical to the success of manufacturers.”
If you are interested in a virtual brochure, which provides manufacturers, end users, and other industry participants with an overview of the latest analysis of the European Molecular Diagnostics Markets (B933-55) then send an e-mail to Radhika Menon Theodore- Corporate Communications at rmtheodore@frost.com with the following information: your full name, company name, title, telephone number, e-mail address, city, state, and country. We will send you the information via email upon receipt of the above information.
European Molecular Diagnostics Markets is part of the Drug Discovery and Diagnostic Technologies Subscription, which also includes research in the following markets: European Clinical Diagnostics Automation Markets, European Immunodiagnostics Automation Markets and, European POCT Markets. All research included in subscriptions provide detailed market opportunities and industry trends that have been evaluated following extensive interviews with market participants. Interviews with the press are available.
Frost & Sullivan, a global growth consulting company, has been partnering with clients to support the development of innovative strategies for more than 40 years. The company’s industry expertise integrates growth consulting, growth partnership services, and corporate management training to identify and develop opportunities. Frost & Sullivan serves an extensive clientele that includes Global 1000 companies, emerging companies, and the investment community by providing comprehensive industry coverage that reflects a unique global perspective and combines ongoing analysis of markets, technologies, econometrics, and demographics. For more information, visit www.frost.com.
European Molecular Diagnostics Markets B933-55 Contact: Radhika Menon Theodore Corporate Communications - Europe P: +91-44-42044541 F: +91-44-24314264 E: rmtheodore@frost.com Melina Trevino Corporate Communications - Americas P: +1-210-247-2440 F: +1-210-348-1003 E: melina.trevino@frost.com Surbhi Dedhia Corporate Communications - India P: +91-22-5001-3431 E: sdedhia@frost.com Jasminder Kaur Corporate Communications - Asia Pacific P: +65-68900937 E: jkaur@frost.com Sharmin Jassal Corporate Communications - Australia P: +61-2-8247-8900 F: +61-2-9252-8066 E: sjassal@frost.comwww.frost.com
Keywords in this release: molecular diagnostics, molecular tests, Europe, markets, European in vitro diagnostics market, IVD, in vitro diagnostics, immunoassays, therapeutic options, population screening programmes, automated molecular diagnostic solutions, integrated molecular diagnostic solutions, assays, molecular diagnostic assays, pharmacogenomics, cancer diagnosis, infectious disease screening, physician awareness programmes, cancer association groups
Frost & Sullivan
CONTACT: Contact: Radhika Menon Theodore, Corporate Communications -Europe, P: +91-44-42044541, F: +91-44-24314264, E: rmtheodore@frost.com,Melina Trevino, Corporate Communications - Americas, P: +1-210-247-2440, F:+1-210-348-1003, E: melina.trevino@frost.com, Surbhi Dedhia, CorporateCommunications - India, P: +91-22-5001-3431, E: sdedhia@frost.com,Jasminder Kaur, Corporate Communications - Asia Pacific, P: +65-68900937,E: jkaur@frost.com, Sharmin Jassal, Corporate Communications - Australia,P: +61-2-8247-8900, F: +61-2-9252-8066, E: sjassal@frost.com
